- Home
- DTSS vs AKTX Comparison
DTSS vs AKTX Comparison
Compare DTSS & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSS
- AKTX
- Stock Information
- Founded
- DTSS 2014
- AKTX N/A
- Country
- DTSS China
- AKTX United States
- Employees
- DTSS N/A
- AKTX N/A
- Industry
- DTSS Computer Software: Prepackaged Software
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- DTSS Technology
- AKTX Health Care
- Exchange
- DTSS Nasdaq
- AKTX Nasdaq
- Market Cap
- DTSS 17.6M
- AKTX 17.2M
- IPO Year
- DTSS N/A
- AKTX N/A
- Fundamental
- Price
- DTSS $1.26
- AKTX $0.45
- Analyst Decision
- DTSS
- AKTX Strong Buy
- Analyst Count
- DTSS 0
- AKTX 2
- Target Price
- DTSS N/A
- AKTX $3.30
- AVG Volume (30 Days)
- DTSS 51.0K
- AKTX 474.3K
- Earning Date
- DTSS 11-13-2025
- AKTX 11-13-2025
- Dividend Yield
- DTSS N/A
- AKTX N/A
- EPS Growth
- DTSS N/A
- AKTX N/A
- EPS
- DTSS N/A
- AKTX N/A
- Revenue
- DTSS $64,349,277.00
- AKTX N/A
- Revenue This Year
- DTSS N/A
- AKTX N/A
- Revenue Next Year
- DTSS N/A
- AKTX N/A
- P/E Ratio
- DTSS N/A
- AKTX N/A
- Revenue Growth
- DTSS 68.56
- AKTX N/A
- 52 Week Low
- DTSS $1.03
- AKTX $0.42
- 52 Week High
- DTSS $3.10
- AKTX $1.73
- Technical
- Relative Strength Index (RSI)
- DTSS 27.94
- AKTX 32.71
- Support Level
- DTSS $1.14
- AKTX $0.42
- Resistance Level
- DTSS $1.40
- AKTX $0.55
- Average True Range (ATR)
- DTSS 0.16
- AKTX 0.06
- MACD
- DTSS -0.04
- AKTX -0.01
- Stochastic Oscillator
- DTSS 22.89
- AKTX 16.03
About DTSS Datasea Inc.
Datasea Inc is a technology company. Its offers provides acoustic business services (focusing on high-tech acoustic technologies and applications such as ultrasound, infrasound, and Schumann resonance), 5G application services (5G AI multimodal digital business), and other products and services to various corporate and individual customers. The business activity of the group functions through China.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.